SCHEMBL9105952

SCHEMBL9105952

Cc1[c]cccc1C(C)c1c[nH]cn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2105209 0.78 ADRA2A (0.38)
Medetomidine SCHEMBL787913 0.76 ADRA2A (0.50)
Dexmedetomidine SCHEMBL12092460 0.76 ADRA2A (0.50)
Dexmedetomidine SCHEMBL119382 0.76 ADRA2A (0.50)
Medetomidine SCHEMBL18497244 0.76 ADRA2A (0.50)
Medetomidine SCHEMBL26432 0.76 ADRA2A (0.50)
Dexmedetomidine SCHEMBL29431568 0.76 ADRA2A (0.50)
Dexmedetomidine SCHEMBL14861666 0.76 ADRA2A (0.50)
Medetomidine SCHEMBL22616139 0.75 ADRA2A (0.49)
Dexmedetomidine SCHEMBL22476079 0.75 ADRA2A (0.49)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3795154-A1 PHARMACEUTICAL COMPOSITION COMPRISING (S)-(3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL FOR USE IN TREATING OCULAR CONDITIONS Allergan, Inc. (US) 2021-03-24 EP disclosed
EP-3093017-B1 PHARMACEUTICAL COMPOSITION COMPRISING (S)-(3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL FOR TREATING OPTIC NEUROPATHY ALLERGAN INC (US) 2021-01-06 EP disclosed
CN-105412092-B Ester prodrugs of [3- (1- (1H-imidazol-4-yl) ethyl) -2-methylphenyl ] methanol for lowering intraocular pressure 阿勒根公司 2020-11-17 CN disclosed
EP-3698789-A1 ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR LOWERING INTRAOCULAR PRESSURE ALLERGAN, INC. (US) 2020-08-26 EP disclosed
EP-3636263-A1 ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL ALLERGAN, INC. (US) 2020-04-15 EP disclosed
EP-3348264-A1 ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR LOWERING INTRAOCULAR PRESSURE ALLERGAN, INC. (US) 2018-07-18 EP disclosed
EP-3053576-B1 ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR LOWERING INTRAOCULAR PRESSURE ALLERGAN INC (US) 2018-05-16 EP disclosed
EP-3050563-B1 ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING SKIN DISEASES AND CONDITIONS ALLERGAN INC (US) 2018-05-09 EP disclosed
EP-3093017-A1 PHARMACEUTICAL COMPOSITION COMPRISING (S)-(3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL FOR USE IN TREATING MAMMALIAN CONDITIONS ALLERGAN, INC. (US) 2016-11-16 EP disclosed
EP-3053576-A1 ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR LOWERING INTRAOCULAR PRESSURE ALLERGAN, INC. (US) 2016-08-10 EP disclosed
EP-3050563-A1 ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING SKIN DISEASES AND CONDITIONS ALLERGAN, INC. (US) 2016-08-03 EP disclosed
EP-2616067-B1 ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL]METHANOL FOR TREATING SKIN DISEASES AND CONDITIONS ALLERGAN INC (US) 2016-05-18 EP disclosed
EP-2616069-A1 ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL]METHANOL Allergan, Inc. (US) 2013-07-24 EP disclosed
EP-2616068-A1 ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL]METHANOL FOR LOWERING INTRAOCULAR PRESSURE Allergan, Inc. (US) 2013-07-24 EP disclosed
US-20120142746-A1 ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR LOWERING INTRAOCULAR PRESSURE ALLERGAN, INC. (US) 2012-06-07 US disclosed
WO-2012037499-A1 ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL ALLERGAN, INC. (US) 2012-03-22 WO disclosed
WO-2012037490-A1 ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR LOWERING INTRAOCULAR PRESSURE ALLERGAN, INC. (US) 2012-03-22 WO disclosed